Prurigo nodularis improvement seen with nemolizumab monother

NEW ORLEANS — Symptoms of prurigo nodularis were significantly improved after 16 weeks of monotherapy with nemolizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.“Prurigo nodularis, PN, is characterized by these intensely itchy nodules that are commonly on the extremities and the trunk,” Shawn G. Kwatra, MD, associate professor of dermatology

Related Keywords

United States , American , Kristen Dowd , Castle Biosciences , Byrebeccal Forand , Arcutis Biotherapeutics , Shawng Kwatra , Regeneron Pharmaceuticals , Amgen , American Academy Of Dermatology Annual Meeting , Genzada Pharmaceuticals Incyte Corp , Johns Hopkins University School Of Medicine , Johns Hopkins Itch Center , Pfizer , Celldex Therapeutics , Novartis Pharmaceuticals Corp , Johnson , Asian Pharmaceuticals , American Academy , Dermatology Annual Meeting , Cara Therapeutics , Genzada Pharmaceuticals , Incyte Corp , Dermatology Annual , Johns Hopkins University School , Peak Pruritis Numerical Rating Scale , Disturbance Numerical Rating Scale ,